Metastatic Solid Tumor Clinical Trials

154 recruitingLast updated: June 17, 2026

There are 154 actively recruiting metastatic solid tumor clinical trials across 39 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1. Top locations include Houston, Texas, United States, Nashville, Tennessee, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Metastatic Solid Tumor Trials at a Glance

154 actively recruiting trials for metastatic solid tumor are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 1 with 140 trials, with the heaviest enrollment activity in Houston, Nashville, and New York. Lead sponsors running metastatic solid tumor studies include Daiichi Sankyo, Innovent Biologics (Suzhou) Co. Ltd., and Eli Lilly and Company.

Browse metastatic solid tumor trials by phase

Treatments under study

About Metastatic Solid Tumor Clinical Trials

Looking for clinical trials for Metastatic Solid Tumor? There are currently 51 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 154 trials

Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 1

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

Advanced Solid TumorMetastatic Solid TumorSolid Tumor+2 more
Memorial Sloan Kettering Cancer Center16 enrolled7 locationsNCT07638371
Recruiting
Phase 1

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.50 enrolled1 locationNCT07607054
Recruiting
Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 1

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumors
Erasca, Inc.200 enrolled5 locationsNCT06983743
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 1

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid Tumor
Coherus Oncology, Inc.154 enrolled30 locationsNCT06657144
Recruiting
Phase 1Phase 2

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Metastatic Solid TumorLocally Advanced Solid TumorEGFR Overexpression
Yuhan Corporation80 enrolled4 locationsNCT06975410
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 2

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.150 enrolled1 locationNCT07646626
Recruiting
Phase 1

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Metastatic Solid TumorsAdvanced Solid CancersAdvanced Malignancy
Adcytherix SAS290 enrolled9 locationsNCT07238075
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Metastatic Solid TumorCancer, Metastatic
Valley Health System72 enrolled1 locationNCT05232409
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled20 locationsNCT07066657
Recruiting
Phase 1Phase 2

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Metastatic Solid TumorAdvanced Cancer
Memorial Sloan Kettering Cancer Center77 enrolled1 locationNCT05004116
Recruiting
Phase 1

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Advanced or Metastatic Solid TumorLiver Failure
Gilead Sciences30 enrolled15 locationsNCT04617522
Recruiting
Phase 1

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorSolid Tumor
Lei Zheng57 enrolled1 locationNCT07086768
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Advanced Solid TumorMetastatic Solid Tumor
Ipsen102 enrolled11 locationsNCT07213830